Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma
Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma
复制标题
DOI：
10.1007/s00066-015-0840-4
复制
发表时间：
2015-08-01
影响因子：
3.1
通讯作者：
Zhang, Li
中科院分区：
文献类型：
--
作者：
Huang, Pei-Yu;Li, Yan;Zhang, Li
目的探讨Aurora-B、FOXM 1、方法采用组织芯片（TMA）免疫组织化学方法检测166例经顺铂（DDP）治疗的鼻咽癌（NPC）患者组织中Aurora-B和FOXM 1的表达。DDP）+氟尿嘧啶（5-FU）诱导化疗和放疗。结果91例肿瘤组织中Aurora-B阳性，93例肿瘤组织中FOXM 1阳性。Aurora-B阴性和Aurora-B阳性组的8年无失败生存率（FFS）分别为65.6%和37.3%（p = 0.024），8年远处FFS（D-FFS）率分别为65.6%和41.5%（p = 0.047）。FOXM 1阴性组的8年总生存率（OS）略高于FOXM 1阳性组（58.4% vs 39.1%，p = 0.081）。考克斯回归分析显示，对于FFS，Aurora-B表达是显著的预后因素（p = 0.025），而对于D-FFS，Aurora-B表达是略微显著的预后因素（p = 0.056）。考克斯回归分析显示FOXM 1表达是影响鼻咽癌患者预后的一个边缘性因素（p = 0.056），相关分析显示Aurora-B和FOXM 1表达无显著相关性。然而，这两个标记没有显著的相关性。
Purpose The purpose of this work was to investigate the relationship between Aurora-B, FOXM1, and clinical outcomes in patients with nasopharyngeal carcinoma (NPC) who were treated with a combination of induction chemotherapy and radiotherapy.Patients and methods The expression of Aurora-B and FOXM1 were investigated by immunohistochemistry using a tissue microarray (TMA) containing samples from 166 NPC patients who were treated with cisplatin (DDP) + fluorouracil (5-FU) induction chemotherapy and radiotherapy between 1999 and 2005. The relationship of Aurora-B, FOXM1, and survival of these NPC patients was analyzed.Results Informative TMA results were obtained in 91 tumor cases for Aurora-B and 93 tumor cases for FOXM1. The 8-year failure-free survival rate (FFS) for the Aurora-B-negative and Aurora-B-positive group was 65.6 and 37.3 %, respectively (p = 0.024), and the 8-year distant FFS (D-FFS) rate was 65.6 and 41.5 %, respectively (p = 0.047). The 8-year overall survival (OS) in the FOXM1-negative group was moderately higher than in the FOXM1-positive group (58.4 vs 39.1 %, p = 0.081). Cox regression analysis revealed that for FFS, Aurora-B expression was a significant prognostic factor (p = 0.025), while for D-FFS, Aurora-B expression was a marginally significant prognostic factor (p = 0.056). When FOXM1 expression was analyzed, the Cox regression analyses showed that FOXM1 expression was a marginally significant prognostic factor (p = 0.056) for OS. Correlation analysis showed that Aurora-B and FOXM1 expression had no significant correlation.Conclusion Aurora-B and FOXM1 were both adverse prognostic markers for NPC patients treated with chemoradiotherapy. However, the two markers had no significant correlation.